Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The Hindi film <keyword id="20300633" type="General" weightage="100" keywordseo="Laapataa-Ladies" source="keywords">Laapataa Ladies</keyword>, directed by <keyword id="19961503" type="General" weightage="20" keywordseo="Kiran-Rao" source="keywords">Kiran Rao</keyword> and produced by <keyword id="20112107" type="General" weightage="20" keywordseo="Jio-Studios" source="keywords" meta.keywordsubtype="org" meta.entityname="Jio Studios" meta.hostid="261" meta.entityid="Jio Studios">Jio Studios</keyword> and <keyword id="20383919" type="General" weightage="20" keywordseo="Aamir-Khan-Productions" source="keywords" meta.keywordsubtype="org" meta.entityname="Aamir Khan Productions" meta.hostid="261" meta.entityid="Aamir Khan Productions">Aamir Khan Productions</keyword>, has achieved a significant milestone by being selected as India’s official entry for the <keyword id="21270192" type="General" weightage="20" keywordseo="Oscars-2025" source="keywords">Oscars 2025</keyword>. This heartfelt and humorous tale has not only won the hearts of audiences across India but has also captured the attention of critics, making it one of the most talked-about films this year. Starring <keyword id="12956111" type="General" weightage="20" keywordseo="nitanshi-goel" source="Orion">Nitanshi Goel</keyword>, Pratibha Ranta, <keyword id="20317162" type="General" weightage="20" keywordseo="sparsh-shrivastav" source="keywords">Sparsh Shrivastav</keyword>, and <keyword id="20065194" type="General" weightage="20" keywordseo="ravi-kishan" source="keywords">Ravi Kishan</keyword>, Laapataa Ladies premiered at the 2023 Toronto International <keyword id="20055573" type="General" weightage="20" keywordseo="film-festival" source="keywords">Film Festival</keyword>, earning accolades from a global audience. Laapataa Ladies tells the story of two brides in rural India who accidentally get swapped during a train journey in 2001, delivering a poignant yet satirical take on patriarchy. With its engaging narrative, the film resonates deeply with viewers and leaves a lasting impact. The film’s success is evident as it enjoyed praise during its theatrical and OTT releases, and even had a special screening at the Supreme Court of India in the presence of Aamir Khan and Kiran Rao. This achievement marks a triumphant return for Kiran Rao, who made her directorial debut with Dhobi Ghat in 2010. Expressing her joy, director Kiran Rao said, "I am deeply honoured and delighted that Laapataa Ladies has been chosen as India’s official entry to the Academy Awards. This recognition is a testament to the tireless work of my entire team, whose dedication and passion brought this story to life." She further added, "Cinema has always been a powerful medium to connect hearts, transcend boundaries, and ignite meaningful conversations. I hope this film will resonate with audiences worldwide, just as it has in India." The film emerged as the unanimous choice of a 13-member selection committee headed by renowned Assamese director Jahnu Barua, who chose Laapataa Ladies from 29 contending films, including notable titles like Srikanth, Vaazhai, Thangalaan, Ullozhukku.

It's official: Kiran Rao's 'Laapataa Ladies' is going to the Oscars 2025!

10 richest women in India in 2024

<keyword id="6354512" type="General" weightage="100" keywordseo="infosys" source="Orion">Infosys</keyword> on Thursday announced the retirement of <keyword id="1440" type="General" weightage="80" keywordseo="kiran" source="Orion">Kiran</keyword> Mazumdar-Shaw as <keyword id="6390711" type="General" weightage="80" keywordseo="independent" source="Orion">Independent</keyword> Director from its Board, effective March 22, 2023, upon completion of her tenure. Accordingly, the Board has appointed D <keyword id="120337" type="General" weightage="80" keywordseo="sundaram" source="Orion">Sundaram</keyword> as the Lead Independent Director of the Company, effective Thursday based on the recommendation of the 'Nomination and Remuneration Committee'. Sundaram has been on the Board of Infosys since 2017. Sundaram serves on the Audit Committee, Risk Management Committee, <keyword id="16919243" type="General" weightage="50" keywordseo="stakeholders-relationship-committee" source="Orion">Stakeholders Relationship Committee</keyword>, Nomination and Remuneration Committee, and Cybersecurity Risk Sub-Committee. "We profusely thank Kiran for having been such an integral member of the Infosys family, providing valuable guidance and leadership to the Board over the years. I am personally very grateful to her as she has been a tremendous ally and amazing colleague on the Board, ever since I re-joined Infosys in August 2017," chairman of Infosys Nandan Nilekani, said. "We also congratulate Sundaram on being appointed as Lead Independent Director and look forward to his continued insight and steadfast support as Infosys continues its growth and transformation journey," Nilekadded. Kiran Mazumdar-Shaw was appointed to the Infosys' Board as an Independent Director in 2014, and as Lead Independent Director in 2018. She also served as the Chairperson of the 'Nomination &amp; Remuneration Committee' and 'CSR Committee', and as a member of the 'Risk Management and ESG Committees' of the Board. "The Board places on record its appreciation for Ms Shaw's invaluable contribution, guidance, and strategic vision, which has helped the Company build and execute a resilient growth strategy," Infosys said in a release. Kiran Mazumdar-Shaw is the Chairperson and Managing Director of Biocon Limited, a biotechnology company based in Bangalore, India. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/former-idbi-gm-conspired-with-vijay-mallya-over-short-term-loan-to-kingfisher-airlines-cbi/articleshow/98936880.cms">Former IDBI GM conspired with Vijay Mallya over short term loan to Kingfisher Airlines: CBI</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/finance/banks/news/fm-nirmala-sitharaman-likely-to-meet-psu-banks-heads-on-saturday/articleshow/98936889.cms">FM Nirmala Sitharaman likely to meet PSU banks heads on Saturday</a>

Kiran Mazumdar-Shaw to retire from Infosys board

Global biopharmaceuticals company <keyword id="6358361" type="General" weightage="100" keywordseo="biocon" source="Orion">Biocon</keyword> on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. "We have had a strong start to the year. At a consolidated level, YoY revenues grew 23 per cent backed by robust growth in both <keyword id="6359687" type="General" weightage="50" keywordseo="biosimilars" source="Orion">Biosimilars</keyword> (29 per cent) and Generics (19 per cent). Core earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 25 per cent and margin improved to 31 per cent compared to 30 per cent in Q1FY22 and net profit grew 71 per cent to Rs 144 crore. "Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains. "All our three businesses are poised for the next phase of strong and sustainable growth which has been challenged during the two years of the Covid-19 pandemic," <keyword id="14575168" type="General" weightage="50" keywordseo="biocon-and-biocon-biologics-executive" source="Orion">Biocon and Biocon Biologics Executive</keyword> <keyword id="10034873" type="General" weightage="20" keywordseo="chairperson-kiran-mazumdar-shaw" source="Orion">Chairperson Kiran Mazumdar-Shaw</keyword> said. Sales of Glargine in the US, and key biosimilars in emerging markets were the main drivers for <keyword id="14245336" type="General" weightage="50" keywordseo="biocon-biologicals" source="Orion">Biocon Biologicals</keyword>' strong performance. <keyword id="10493627" type="General" weightage="50" keywordseo="biocon-biologics-ltd" source="Orion">Biocon Biologics Ltd</keyword> Managing Director <keyword id="287851" type="General" weightage="50" keywordseo="arun-chandavarkar" source="Orion">Arun Chandavarkar</keyword> said: "Initiation of global clinical trials for two monoclonal antibodies and advancement of our other pipeline assets led to a 120 per cent increase in our research and development investments this quarter. Whilst this impacts EBITDA in the near term, such investments will create a strong portfolio to secure our future growth. "Our strategic alliance with Serum Institute Life Sciences for vaccines and the acquisition of Viatris' global biosimilars business are on track for closure in the second half of this calendar year." SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/reduction-in-rice-cereals-sown-area-worrisome-bank-of-baroda/articleshow/93175801.cms">Reduction in rice, cereals sown area worrisome: Bank of Baroda</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/oppo-pad-air-review-sleek-and-stylish-but-short-on-power/articleshow/93165775.cms">Oppo Pad Air review: Sleek and stylish but short on power</a>

Biocon Q1FY23 revenue up 23% at Rs 2,217 cr

<ul><li><keyword id="6379793" type="General" weightage="100" keywordseo="falguni-nayar" source="Orion">Falguni Nayar</keyword> is the richest self-made billionaire with a net worth of ₹57,520 crore.</li><li>However, <keyword id="1490249" type="General" weightage="20" keywordseo="Roshni-Nadar-Malhotra" source="Orion">Roshni Nadar Malhotra</keyword> of HCL Technologies is the wealthiest woman, as per Kotak Private Banking Hurun list.</li><li>Around 25 new women have entered into the list this year, says the report.</li></ul>It’s beauty over biotech as Falguni Nayar overtook Biocon’s <keyword id="6413985" type="General" weightage="20" keywordseo="kiran-mazumdar-shaw" source="Orion">Kiran Mazumdar-Shaw</keyword> as India’s richest self-made woman with a wealth of ₹57,520 crore, as per Kotak Private Banking Hurun’s list of India’s wealthiest women. Nayar’s ranking went up nine places in the list, after the company she founded, Nykaa, went public last year. Roshni Nadar Malhotra of HCL Technologies however retained her title as the wealthiest woman on the list with ₹84,330 crore, for the second year in a row. Around 25 new women have entered into the list this year, says the report. The report further highlights that the cut-off wealth required to feature in the list has almost tripled since last year to ₹300 crore. The women on the 2021 list have an average wealth of around ₹4,170 crore as against ₹2,725 crore in the last year. “Over the years, Indian women are slowly yet surely coming into their own - carving a space for themselves through knowledge, excellence, passion, and empathy,” said <keyword id="14568875" type="General" weightage="80" keywordseo="oisharya-das" source="Orion">Oisharya Das</keyword>, CEO – private banking, <keyword id="46013" type="General" weightage="50" keywordseo="kotak-mahindra-bank" source="Orion">Kotak Mahindra Bank</keyword>. The list is based on the net worth of women as on 31 st December, 2021. <cmsannotation type="cmsannotation" annotationid="More younger women are becoming self-made billionaires" comment="subhead" text="More younger women are becoming self-made billionaires">More younger women are becoming self-made billionaires</cmsannotation> Even though the founder of Biocon, Shaw, was displaced — her sector pharmaceuticals too saw the most number of new entrants, followed by healthcare and consumer goods. 9 out 20 women under the age of 40 years or younger category are self-made, according to the report. Three professional managers also made it to the list. Pepsico’s <keyword id="6421975" type="General" weightage="80" keywordseo="indra-nooyi" source="Orion">Indra Nooyi</keyword> is the richest professional manager, with a wealth of ₹5,040 crore. And, 33-year-old Kanika Tekriwal of Jetsetgo is the youngest self-made woman. “Women-led wealth creation directly improves women’s employment, corresponding families, and society. Inclusion of women, who represent 50% of India’s population in the workforce or wealth creation, cuts across societal barriers,” said <keyword id="2672295" type="General" weightage="80" keywordseo="anas-rahman-junaid" source="Orion">Anas Rahman Junaid</keyword>, MD and chief researcher at <keyword id="3656834" type="General" weightage="50" keywordseo="hurun-india" source="Orion">Hurun India</keyword>. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/telecom/news/5g-spectrum-auctions-big-money-is-in-but-no-bidding-war-yet/articleshow/93156289.cms">5G spectrum auctions: Big money is in but no bidding war yet</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/apps/news/a-massive-data-breach-in-2020-impacted-3-4-million-paytm-usersheres-how-to-find-out-if-your-data-was-compromised/articleshow/93157246.cms">A massive data breach in 2020 impacted 3.4 million Paytm users – here’s how to find out if your data was compromised</a>

Nykaa’s Falguni Nayar overtakes Kiran Mazumdar Shaw as the richest self-made Indian woman

<ul><li>The International Consortium of Investigative Journalists (ICIJ) has announced <keyword id="12235620" type="General" weightage="20" keywordseo="Pandora-Papers" source="Orion">Pandora Papers</keyword>, a leak that consists of offshore dealings routed through tax havens across the globe.</li><li>The list includes hundreds of Indians, dozens of whom are prominent and already under investigation by Indian authorities.</li><li>Here’s everything we know so far about the Indians involved in Pandora Papers.</li></ul><keyword id="12237221" type="General" weightage="20" keywordseo="Pandora-Papers-leak" source="Orion">Pandora Papers leak</keyword> includes several prominent Indian names, including cricketing legend Sachin Tendulkar and <keyword id="9171" type="General" weightage="20" keywordseo="Anil-Ambani" source="Orion">Anil Ambani</keyword>, the beleaguered brother of India’s richest person. Over 300 Indian names have been spotted in the leak - the biggest one yet, bigger than even the Panama Papers leak which rocked the world in 2016. The Ministry of Finance took note of the revelations made in the Pandora Papers leak today evening. "The relevant investigative agencies would undertake investigation in these cases and appropriate action would be taken in such cases as per law," stated a <a href="https://twitter.com/IncomeTaxIndia/status/1445015165523546115" data-type="tilCustomLink">press release</a> issued by the ministry. An official spokesperson of India's Central Board of Direct Taxes (CBDT) has said that the revelations of the Pandora papers will be investigated. As per a statement to ANI, a team consisting of representatives from CBDT, Enforcement Directorate, Reserve Bank of India and Financial Intelligence Unit will soon begin the investigation. The investigation will be headed by the Chairman of CBDT. It is worth pointing out that while many of these investments routed through offshore firms are done with the objective of tax avoidance and maintaining secrecy, some of them are legitimate and declared to the relevant authorities in India. That said, here’s everything we know so far about the Pandora Papers leak and the Indians named in it so far: <cmsannotation type="cmsannotation" annotationid="Over 300 Indians in Pandora Papers leak" comment="subhead" text="Over 300 Indians in Pandora Papers leak">Over 300 Indians in Pandora Papers leak</cmsannotation> According to an Indian Express report, there are over 300 Indian names in the Pandora Papers leak, including over 60 prominent ones. The report adds that these will be corroborated and revealed in the coming days. These are some of the people named in the reports. <cmsannotation type="cmsannotation" annotationid="Anil Ambani" comment="subhead" text="Anil Ambani">Anil Ambani</cmsannotation> <div type="image" title="Anil Ambani" msid="86745697" hostid="261"><payload><![CDATA[Anil Ambani]]></payload></div> The beleaguered brother of India’s richest person has found his name in the papers, accusing him of setting up 18 offshore firms that have borrowed and invested $1.3 billion, one of which shares a promoter firm that owns Reliance Capital listed in India. “The Reliance Group conducts business globally and for legitimate business and regulatory requirements, companies are incorporated in different jurisdictions,” a lawyer on behalf of Anil Ambani <a href="https://indianexpress.com/article/express-exclusive/anil-ambani-pandora-papers-7550155/">told the Indian Express</a>. <cmsannotation type="cmsannotation" annotationid="Sachin Tendulkar" comment="subhead" text="Sachin Tendulkar">Sachin Tendulkar</cmsannotation> <div type="image" title="Sachin Tendulkar" msid="86745715" hostid="261" caption="&amp;lt;p&amp;gt;Sachin Tendulkar&amp;lt;/p&amp;gt;"></div> Cricketing legend Sachin Tendulkar had reportedly set up a firm way back in 2007, which was liquidated in 2016, valued at roughly $8.6 million. <a href="https://indianexpress.com/article/express-exclusive/sachin-tendulkar-pandora-papers-panama-expose-7550138/">According</a> to the CEO and Director of the Sachin Tendulkar Foundation, these investments are legitimate and declared in Tendulkar’s tax returns. <cmsannotation type="cmsannotation" annotationid="Nirav Modi" comment="subhead" text="Nirav Modi">Nirav Modi</cmsannotation> <div type="image" title="Nirav Modi" msid="86745727" hostid="261" caption="&amp;lt;p&amp;gt;Nirav Modi and Mehul Choksi&amp;lt;/p&amp;gt;"></div> His sister, Purvi Modi, set up a trust in the British Virgin Islands a month before he fled in January 2018. She has been named accused in a $2 billion money laundering case filed against Nirav Modi and Mehul Choksi. <cmsannotation type="cmsannotation" annotationid="Niira Radia" comment="subhead" text="Niira Radia">Niira Radia</cmsannotation> <div type="image" title="Niira Radia" msid="86745766" hostid="261" caption="&amp;lt;p&amp;gt;Niira Radia&amp;lt;/p&amp;gt;"></div> Corporate lobbyist Niira Radia has reportedly set up a dozen firms, conducting her offshore transactions through Sanjay Newatia, a former Credit Suisse banker. An <a href="https://indianexpress.com/article/express-exclusive/pandora-papers-niira-radia-corporate-lobbyist-7550207/">Indian Express report</a> suggests that her name is linked to a dozen offshore firms, an allegation which Radia declines and states “accurate disclosures have been made to all relevant authorities. <cmsannotation type="cmsannotation" annotationid="Gandhi family friend Satish Sharma" comment="subhead" text="Gandhi family friend Satish Sharma">Gandhi family friend Satish Sharma</cmsannotation> <div type="image" title="Satish Sharma - Priyanka Gandhi Vadra" msid="86745776" hostid="261" caption="&amp;lt;p&amp;gt;Satish Sharma with the Gandhi family&amp;lt;/p&amp;gt;"></div> A Gandhi family friend and former Congress leader, Satish Sharma set up a trust in 1995 when he was the Petroleum and Natural Gas minister. He also set up another trust in 2015 when he was a Rajyasabha member. Sharma was the protector of both, the Jan Zegers and JZ II trusts, and his wife a beneficiary. In a response to <a href="https://indianexpress.com/article/express-exclusive/pandora-papers-satish-sharma-congress-7550193/">The Indian Express</a>, Sharma’s wife, Sterre Sharma, noted that these trusts were set up to “manage his assets and pass on his inheritance” to the listed beneficiaries. <cmsannotation type="cmsannotation" annotationid="Cox and Kings’ Ajit Kerkar" comment="subhead" text="Cox and Kings’ Ajit Kerkar">Cox and Kings’ Ajit Kerkar</cmsannotation> Ajit Kerkar, now in jail, set up two trusts in the British Virgin Islands in 2010 and has connections with at least half a dozen offshore firms set up between 2010 and 2016. Most of these firms were reportedly set up by Kerkar and Shyam Maheshwari, who is a partner at Ares SSG group, an investment firm. The trusts set up by Kerkar are guarantors for loans amounting to $79 million. <cmsannotation type="cmsannotation" annotationid="Kiran Mazumdar Shaw" comment="subhead" text="Kiran Mazumdar Shaw">Kiran Mazumdar Shaw</cmsannotation> <div type="image" title="Kiran Shaw" msid="86745794" hostid="261" caption="&amp;lt;p&amp;gt;Kiran Mazumdar Shaw&amp;lt;/p&amp;gt;"></div> Her husband, a British Citizen, has reportedly set up an entity that holds 19.76% in Biocon, and has $85 million in various assets, including cash and real estate. Glentec is registered with RBI and SEBI, Shaw reportedly said, in response to queries raised by the Indian Express. <cmsannotation type="cmsannotation" annotationid="Not all investments are illegitimate" comment="subhead" text="Not all investments are illegitimate">Not all investments are illegitimate</cmsannotation> While some of the investments made by the people reported in the Pandora Papers leak could have been done to avoid taxes, they are not illegitimate if the required disclosures have been made to the relevant authorities. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/irctc-hindustan-aeronautics-zydus-wellness-and-5-others-hold-dominant-positions-in-the-market/slidelist/86736871.cms">These 8 valuable companies rule their sectors with a huge piece of the pie</a> <a href="https://www.businessinsider.in/finance/news/billionaires-and-world-leaders-including-putin-and-king-abdullah-stashed-vast-amounts-of-money-in-secretive-offshore-systems-leaked-documents-find/articleshow/86738076.cms">Billionaires and world leaders, including Putin and King Abdullah, stashed vast amounts of money in secretive offshore systems, leaked documents find</a>

Anil Ambani, Sachin Tendulkar, Kiran Shaw and other Indians named in the Pandora Papers leak

<ul><li><a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink">Global Trends Festival</a> is one of the world's most prestigious events which will be live from Oct 19-23.</li><li>While nobel laureates, some of the biggest political and corporate icons will provide thought leadership, it's a great platform to network with CXOs from around the world.</li><li><a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink">Global Trends Festival 2020</a> is presented by <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://aws.amazon.com/" data-type="tilCustomLink">AWS</a>.</li><li>Register for the <keyword id="10088455" type="UNKNOWN" weightage="20" keywordseo="global-trends-festival">Global Trends Festival</keyword> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/trendsform_2020.cms" data-type="tilCustomLink">here</a>.</li></ul> Kiran Mazumdar Shaw is India's richest self-made woman. She started Biocon at the age of 25 and has built it up into the country's largest pharmaceutical company. Her journey to the top was no easy task, but Shaw is known for her thinking and vision. Shaw could foresee the potential and opportunity in the biotech space, and she capitalised on it. Shaw calls herself an "accidental entrepreneur." She wanted to become India's first woman brewmaster. When those plans met with resistance in India, she set her sights on the industrial enzyme-producing business and marched on to conquer the biopharma space in the 90s. In 2014, Biocon was India's first biotech company to go public, and it hit the <a href="https://www.businessinsider.in/thelife/personalities/news/indias-second-richest-woman-kiran-mazumdar-shaw-nearly-doubles-her-wealth-to-4-6-billion-during-the-covid-19-pandemic/articleshow/78569565.cms">$1 billion mark</a> on the day it listed. There has been no looking back since. Kiran Mazumdar Shaw believes that women play an essential role in economic development, and their contribution has been ignored for a long time. "It's a myth to think that women are not bold enough to run daring businesses. It's a myth that all of us have busted time. So, I'm really surprised that the world still doesn't get it," she told <a href="https://www.businessinsider.in/thelife/personalities/news/kiran-mazumdar-shaw-wanted-to-be-a-brewmaster-before-founding-the-largest-biotech-company-in-india/articleshow/74508921.cms">Twitter </a>in an interview earlier this year. A pioneer of the biotech industry in India, Shaw has been conferred upon with Padma Shri and the Padma Bhushan. She believes that entrepreneurship is not about making the moolah but having a purpose, and one must always think about giving back to society. In fact, Shaw can tell the Covid-19 story as a survivor and a healer. After all, she has the first-hand experience — as the 67-year old tested positive in mid-August and recovered by the end of the month. And her $7 billion company, Biocon's repurposed drug, Itolizumab, is used to treat the dreaded virus for emergency cases. However, the drug is not a part of the government's clinical management protocol for COVID-19 treatment yet. At the Global Trends Festival 2020, Shaw will share insights on why entrepreneurs must be risk-takers, her journey as a businesswoman, and unlocking India's suppressed potential. SEE ALSO: <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/guenter-butschek-will-speak-about-the-much-needed-electric-push-towards-a-greener-future-at-the-global-trends-festival/articleshow/78642212.cms" data-type="tilCustomLink">Guenter Butschek will speak about the much needed electric push towards a greener future at the Global Trends Festival</a> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/hear-and-learn-from-byju-raveendran-the-man-who-made-online-classes-fun-years-before-covid-at-the-global-trends-festival-2020/articleshow/78641694.cms" data-type="tilCustomLink">Hear and learn from Byju Raveendran, the man who made online classes fun, years before COVID, at the Global Trends Festival 2020</a> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/dont-miss-rana-daggubati-speak-about-the-future-of-storytelling-at-the-global-trends-festival-2020/articleshow/78630087.cms" data-type="tilCustomLink">Don’t miss Rana Daggubati speak about the future of storytelling at the Global Trends Festival 2020</a>

Catch Kiran Mazumdar Shaw at the Global Trends Festival 2020, speak about unlocking India's suppressed potential

<ul><li>Half of the billionaires, including Mukesh Ambani, Radhakishan Damani, Gautam Adani, Cyrus Poonawalla, saw significant gains in their wealth. </li><li>The biggest percentage gainer was 67-year old Kiran Mazumdar-Shaw, Biocon founder and the second richest woman in India. </li><li>While Biocon has joined the race to discover the vaccine, Shaw was not immune to COVID-19. She tested positive in August and recovered in a fortnight. </li></ul>India’s super-rich club of 100 people has added nine new faces and about $88 billion collectively during the coronavirus pandemic — which is assumed to be far worse than the Great Depression. Half of the billionaires, including Mukesh Ambani, Radhakishan Damani, Gautam Adani, Cyrus Poonawalla saw significant gains — taking the collective net worth of 100 billionaires to $517.5 billion, <a href="https://www.forbes.com/sites/naazneenkarmali/2020/10/07/indias-100-richest-2020-collective-net-worth-of-countrys-richest-rose-14-despite-pandemic/#2cf4d5e93da4">Forbes reported. </a> The biggest percentage gainer was 67-year old Kiran Mazumdar-Shaw, Biocon founder and the second richest woman in India. Her wealth has nearly doubled from $2.38 billion in 2019 to $4.6 billion in 2020 — a whopping 93.28% gain among India's 100 richest. She is one of the only five women billionaires in India. <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword> started her Indian-based pharma company about 42 years ago with merely two employees and $500 funds. However, it was not until 2014 that her company became a publicly-traded entity. It touched the $1billion mark on the very day it listed. Over the past decade, Biocon has grown by leaps and bounds to become a $5 billion company. In just the last 12 months, Biocon’s share price has surged 99% from ₹233 in October 2019 to ₹464.70 currently. <div type="image" title="Biocon11" msid="78569590" hostid="261"></div> While her company has joined the race to discover a vaccine to fight the virus, Shaw wasn’t immune to it. On August 16, she tested positive for COVID-19 and recovered 15 days later. Shaw has been vocal about leveraging science to contain the virus. Three months after coronavirus broke out in India, Biocon announced that it would launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around ₹8,000 per vial. The pharmaceutical is set to begin the phase-4 trials of the potential drug. Well, Shaw might have gained the most, but Mukesh Ambani’s record gains have left everyone behind. He remains India’s richest man for the 13th year in the running and leads by a large margin. Ambani added $37.3 billion to his fortune, thanks to the trail of investments in Reliance Jio and his retail venture. Jio alone got $20 billion investments from investors like Google, Facebook, and Microsoft. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/tcs-beats-accenture-to-become-the-worlds-most-valuable-it-services-company/articleshow/78566487.cms">TCS beats Accenture to become the world’s most valuable IT services company — but this not the first time it has raced ahead</a>

India’s second richest woman nearly doubles her wealth to $4.6 billion during the COVID-19 pandemic

<ul><li><keyword id="26776" type="PERSON" weightage="20" keywordseo="Kiran-Kumar">Kiran Kumar</keyword> has tested positive for <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword> and is currently under home quarantine. The 74-year-old <keyword id="271" type="POSITION" weightage="20" keywordseo="actor">actor</keyword> said he is asymptomatic and is doing "absolutely fine." </li><li>The actor, who had featured in films like "Dhadkan", "Mujhse Dosti Karoge", among others, said it has been ten days since the test happened and he still hasn't developed any symptoms. </li><li>As of Saturday, Maharashtra recorded total 47,190 coronavirus cases, with 1,577 death toll, according to the state health department.</li></ul> Veteran film and TV actor Kiran Kumar has tested positive for coronavirus and is currently under home quarantine. The 74-year-old actor said he is asymptomatic and is doing "absolutely fine." "I am asymptomatic. On May 14, I went to the hospital for a medical check-up, where the <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">COVID-19</keyword> test was mandatory. So I got myself tested and the result was positive. "But I had no symptoms then, nor do I have any now. There's no fever, no cough, I'm fine and have self quarantined at home," Kumar told . The actor, who had featured in films like "Dhadkan", "Mujhse Dosti Karoge", among others, said it has been ten days since the test happened and he still hasn't developed any symptoms "My family lives on the second floor of the building and I'm currently on the third floor. On May 26 or May 27, I am going to get my second test done. At the moment I'm absolutely fine," he added. As of Saturday, Maharashtra recorded total 47,190 coronavirus cases, with 1,577 death toll, according to the state health department.

Actor Kiran Kumar tests positive for COVID-19

<ul><li><keyword id="6358361" type="DEFINITION" weightage="20" keywordseo="biocon">Biocon</keyword> has joined the list of other pharma giants like Glenmark, Hetero, and Cipla which rolled out repurposed drugs to treat COVID-19 patients in India. </li><li>Itlolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe coronavirus cases. </li><li>Previously, Biocon along with Cipla, Hetero Labs, Jubilant Lifesciences and Mylan got voluntary permission from Gilead Sciences to produce Remdesivir in India. </li><li>Biocon’s subsidiary Biocon Biologics <a href="https://www.ndtv.com/business/biocon-subsidiary-biocon-biologics-received-nod-to-use-cytosorb-in-covid-19-coronavirus-treatment-2235772">also received approval</a> from the Drugs Controller General of India to use extracorporeal blood purification (EBP) device CytoSorb to treat coronavirus patients. </li></ul>Indian pharmaceutical giant Biocon Limited on July 11 got approved from the Drugs Controller General of India for the use of its biologic drug Itolizumab to treat moderate and severe coronavirus patients. The shares of Kiran Mazumdar Shaw-led Biocon rose by nearly 10% after it announced that it has received an emergency use authorisation for Itolizumab. Though the shares have cooled down since the net gains from the stock are over 65% in less than 90 days. <div type="image" title="BIOCON" msid="76936314" hostid="261"></div> While most businesses have struggled to keep their operations up and running during the pandemic, drug makers have been essential in the fight against COVID-19. Biocon has joined the list of other pharma giants like Glenmark, Hetero, and Cipla which rolled out repurposed drugs to treat COVID-19 patients in India. These repurposed drugs were designed to treat other diseases but their generic version is now used to cure coronavirus. However, very few stocks, even within the pharmaceuticals universe, have performed as well as Biocon has. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stocks </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">QTR %</td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Biocon </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">25.51% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Lupin </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">10.67% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cadila Health </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2.08% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">9.99% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Alkem Laboratories </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-11.66% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr. Reddys Lab </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">7.74 </td></tr></tbody></table>Source: ET READ ALSO: <a href="https://www.businessinsider.in/india/news/fabiflu-covifor-cipremi-medicines-approved-to-treat-covid-19-patients-in-india/slidelist/76507980.cms">Fabiflu, Covifor, Cipremi and other drugs approved or under trial for COVID-19 patients in India</a> Biocon has at least two drugs being used to treat COVID-19 Itlolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe coronavirus cases. The firm has repurposed the drug, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as Alzumab for treating chronic plaque psoriasis, a skin disease. Itlolizumab will be manufactured and formulated as an intravenous injection at Biocon Park in Bengaluru. The pharma <a href="https://www.businesstoday.in/sectors/pharma/coronavirus-treatment-biocons-psoriasis-drug-itolizumab-approved-by-dcgi-full-course-for-rs-32000/story/409574.html">giant might charge ₹32,000 for the full course</a> of the drug. Previously, Biocon along with Cipla, Hetero Labs, Jubilant Lifesciences and Mylan got voluntary permission from Gilead Sciences to produce Remdesivir in India. Remdesivir is an antiviral drug that was first used to treat Ebola. Biocon’s subsidiary Biocon Biologics <a href="https://www.ndtv.com/business/biocon-subsidiary-biocon-biologics-received-nod-to-use-cytosorb-in-covid-19-coronavirus-treatment-2235772">also received approval</a> from the Drugs Controller General of India to use extracorporeal blood purification (EBP) device CytoSorb to treat coronavirus patients. CytoSorb, according to Shaw, is a unique device which reduces cytokine storm in critically ill coronavirus patients and was first introduced in India in 2013. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/amazon-reportedly-told-employees-they-have-to-delete-tiktok-from-their-phones-due-to-security-risks/articleshow/76900325.cms">Amazon told employees to delete TikTok from their phones — then walked back the policy and said it was an 'error'</a> <a href="https://www.businessinsider.in/india/news/photographer-of-the-viral-black-panther-images-from-india-shares-his-story/articleshow/76830618.cms">INTERVIEW: Shaaz Jung opens up about the blood, sweat and years behind the viral images of a rare black panther</a> <a href="https://www.businessinsider.in/tech/news/intel-will-speed-up-mukesh-ambanis-5g-run-power-him-with-ai-and-possibly-a-jio-laptop/articleshow/76780290.cms">Intel will speed up Mukesh Ambani’s 5G run, power him with AI and possibly a Jio laptop⁠— all in return for massive amount of data</a>

₹10,000 invested in Biocon just before lockdown is now worth over ₹16,500⁠— here’s why

India’s richest women as per Hurun list: Kiran Mazumdar Shaw and Smita Crishna on top

<ul><li>The Chief Minister of <keyword id="6354306" type="COMPANY" weightage="20" keywordseo="Puducherry">Puducherry</keyword> has tendered his resignation to Lieutenant Governor Tamilisai Soundararajan after losing the floor test in the Legislative Assembly today, February 22.</li><li>He has accused the Bharatiya Janata Party (BJP) and former Lieutenant Governor <keyword id="6354361" type="PERSON" weightage="20" keywordseo="Kiran-Bedi">Kiran Bedi</keyword> of trying to topple the government.</li><li>According to Narayanasamy, the central government was undermining the UT government and depriving it of the required funds.</li></ul>As the union territory of Puducherry gears up for its assembly elections in May, the political crisis, after the ruling coalition’s two MLAs resigned on Sunday, has taken a massive turn. The confidence motion moved by <keyword id="3449433" type="PERSON" weightage="20" keywordseo="chief-minister-V-Narayanasamy">Chief Minister V Narayanasamy</keyword> in the Assembly was defeated today, February 22. Following the confidence vote debacle, Narayanasamy tendered his resignation to Lieutenant Governor Tamilisai Soundararajan. "Myself, ministers, Congress and DMK MLAs and independent legislators have tendered resignation and sought it be accepted," he told reporters. <div type="twitter" handle="ANI" handlename="ANI" image="http://pbs.twimg.com/profile_images/1497864299/ani_mic_logo_normal.jpg" favoritecount="2063" retweetcount="206" status="Puducherry Chief Minister submits resignation to the Lieutenant Governor after losing majority in the Assembly https://t.co/Y2posu1zXQ" createdat="1613975547000" id="1363738404299501569"></div> The floor test came after the Puducherry Lieutenant Governor Tamilisai Soundararajan asked Chief Minister V Narayanasamy to prove his government’s majority in the Vidhan Sabha. A test that the Congress-Dravida Munnetra Kazhagam (DMK) alliance failed. While moving the motion, Narayanasamy pointed fingers at the Bharatiya Janata Party (BJP) and former Lieutenant Governor Kiran Bedi for trying to topple the government. “Former LG Kiran Bedi and the Central Government colluded with the opposition and tried to topple the government. It is clear that the people of Puducherry trust us. This is a government elected by the people,” he said. <div type="twitter" handle="ANI" handlename="ANI" image="http://pbs.twimg.com/profile_images/1497864299/ani_mic_logo_normal.jpg" favoritecount="252" retweetcount="16" status="Puducherry CM V.Narayanasamy arrives at the assembly, to face floor test today https://t.co/DzVwxtQqZf" createdat="1613967680000" id="1363705406594277377"></div> According to Narayanasamy, the central government was undermining the UT government and depriving it of the required funds. "What is happening in Puducherry now is political prostitution. But the truth will prevail," he said in his speech ahead of the floor test accusing BJP of derailing India's democratic system. Following his scathing speech and heated arguments over the voting rights of three nominated MLAs who support the BJP, the Chief Minister and ruling MLAs walked out of the house The numbers were stacked against Congress-DMK The Puducherry Assembly is made up of 33 seats. Of these, 30 are for elected MLAs and three are for MLAs nominated by the central government. During the 2016 Assembly elections, the Congress was able to garner 15 of these seats putting them in the majority. However, one of their MLAs was disqualified by the party last year under the anti-defection law. Another five have since resigned, including one who quit on Sunday, February 21. This meant that the overall strength of the Legislative Assembly was now down to 26 and the Congress alliance was holding on to 12 of those seats — one short of the halfway mark. And, since one of the members is also the speaker, his vote doesn’t count unless there’s a tie, leaving the Congress’ strength effectively only at 11. The opposition, on the other hand, has 14 seats in its kitty, including the three nominated members. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Party </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">MLAs in the Puducherry Legislative Assembly </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Congress </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">9 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">DMK </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Independent </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">NR Congress </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">7 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">AIADMK </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">4 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Nominated MLAs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">3 </td></tr></tbody></table> The opposition is reportedly in discussion with the alliance partners to decide whether it wants to stake a claim to form a new government in Puducherry. SEE ALSO: <a href="https://www.businessinsider.in/business/ecommerce/news/discounts-have-dropped-lower-on-the-customer-priority-list-say-indian-online-retailers/articleshow/81145830.cmshttps://www.businessinsider.in/business/ecommerce/news/discounts-have-dropped-lower-on-the-customer-priority-list-say-indian-online-retailers/articleshow/81145830.cms">Discounts have dropped lower on the customer’s priority list, say Indian e-tailers</a> <a href="https://www.businessinsider.in/finance/news/heres-how-to-avail-gst-credit-if-your-supplier-has-not-uploaded-invoices/articleshow/81145678.cms">Here’s how to avail GST credit if your supplier has not uploaded invoices</a> <a href="https://www.businessinsider.in/careers/news/deutsche-bank-plans-to-hire-1000-freshers-in-india-as-it-looks-to-build-core-technologies-in-house/articleshow/81147886.cms">INTERVIEW: Deutsche Bank plans to hire 1,000 freshers in India as it looks to build core technologies in-house</a>

Puducherry Chief Minister V Narayanasamy resigns after Congress-led govt loses majority

<ul><li>On June 5, Biocon’s Executive <keyword id="9348685" type="PERSON" weightage="20" keywordseo="chairperson-kiran-mazumdar-shaw">Chairperson Kiran Mazumdar Shaw</keyword> was named as <keyword id="9348456" type="UNKNOWN" weightage="20" keywordseo="ey-world-entrepreneur-of-the-year">EY World Entrepreneur of the Year</keyword> 2020. </li><li>With this, she joined Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys, who were awarded with this honour in 2014 and 2005, respectively. </li><li>She founded the India-based pharma company Biocon with merely two employees and funds worth $500. </li><li>In 2014, Biocon became the first biopharma company to be a publicly-traded entity and the second company to touch the $1 billion mark on the very first day of the listing.</li></ul>In 1978, <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword> founded the India-based pharma company Biocon with merely two employees and funds worth $500. 42 years later, Shaw has been named as <keyword id="9348684" type="UNKNOWN" weightage="20" keywordseo="ey-world-entrepreneur">EY World Entrepreneur</keyword> of the Year 2020. <div type="twitter" handle="EY_EOY" handlename="EY EOY" image="http://pbs.twimg.com/profile_images/877518155282878464/HTnSrpib_normal.jpg" favoritecount="302" retweetcount="123" status="Congratulations to @kiranshaw, Executive Chairperson of India-based @Bioconlimited who is named EY World Entreprene… https://t.co/eYxchprTNh" createdat="1591297093000" id="1268618074879438853"></div> With this, she has joined the likes of Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys, who were awarded with this honour in 2014 and 2005 respectively. The virtual award ceremony was held on June 5 — and she was chosen from over 46 entrepreneurs from 41 countries. “She has built India's largest biopharmaceutical company on a foundation of compassionate capitalism and putting patient needs before profits,” Chair of the EY World Entrepreneur Of The Year judging panel <a href="https://www.prnewswire.com/in/news-releases/dr-kiran-mazumdar-shaw-from-india-named-ey-world-entrepreneur-of-the-year-tm-2020-883966722.html">said</a>. An aspiring Brewmaster who opened a bio-enzymes company <div type="image" title="eea0f7895182bcc364abaeda35e570da" msid="76208305" hostid="261"></div> Kiran, who graduated from Australia in 1975 wanted to work as a Brewmaster — a person who looks after everything that goes in the process of making a beer. Little did she know, the brewing industry — which is highly male-dominated in India — will not accept a woman in the role. But, that did not stop her. Two years down the line, she started Biocon in a rented house in Bengaluru where they produced the bio enzymes in the garage. A year of struggle and Biocon became the first such company in India that exported enzymes to other countries like the US and Europe. Years later, in 2004, she came up with <keyword id="1829392" type="COMPANY" weightage="20" keywordseo="Biocon-Foundation">Biocon Foundation</keyword> — which aims to provide healthcare and sanitation facilities and diagnosis and treatment of cancer and other non-communicable diseases to weaker sections of the society. Bicon goes public <div type="image" title="06c05f1aefb71a5e6abe2fa9b1bd87fa" msid="76208327" hostid="261"></div> In 2014, Biocon became the first biopharma company to be a publicly-traded entity and the second company to touch the $1 billion mark on the very first day of the listing. Over the years, the bio-enzymes major — which is now one of the prominent biotech giants in Asia — grew multifold to become a <a href="https://www.businessinsider.in/stock-market/news/biocon-share-price-falls-after-earnings-and-mutual-funds-stake-in-the-stock/articleshow/75754048.cms">$5 billion company</a>. Today, Biocon provides healthcare requirements like insulin for diabetes, biosimilars for those fighting cancer, arthritis and other severe diseases. The company reported revenue worth $800 million, as of FY19 and employees more than 11,000 people. In fact, Biocon has created its mark where other pharma giants are struggling and has a presence in over 120 countries. That includes fermentation-based molecules, human insulin, contract research services and more. That may be because of the affordability of the products. In September 2019, Biocon announced the supply of a special kind of insulin to middle income companies on low prices — in fact, less than a third of the current prices. Meanwhile, Shaw has been an angel investor for a lot of startups in the healthcare domain including those in areas like breast cancer screening, chemotherapy and others. In times of the global pandemic While the world is waiting with bated breath for a vaccine to treat coronavirus, Shaw believes that it will take <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">at least nine months for the COVID-19 vaccine to enter clinical trials</a> in India. She also said that there will be multiple waves before the coronavirus curve flattens as community spread remains a key challenge in India. See also: <a href="https://www.businessinsider.in/business/news/mubadala-to-buy-1-85-pc-stake-in-jio-platforms-for-rs-9093-6-cr/articleshow/76205654.cms?upcache=2">Abu Dhabi's Mubadala to buy 1.85% stake in Ambani's Jio Platforms for ₹9093.6 crore</a> <a href="https://www.businessinsider.in/policy/foreign-policy/news/a-former-diplomat-explains-why-four-agreements-will-take-india-and-australia-ties-to-the-next-level/articleshow/76206931.cms">Beyond ‘khichdi’ and ‘samosa’ ⁠— a former diplomat explains why four agreements will take India and Australia ties to the next level</a>

You Searched For "kiran" and got 13 results

It's official: Kiran Rao's 'Laapataa Ladies' is going to the Oscars 2025!

BI India Bureau

10 richest women in India in 2024

Ashmita Gupta

Kiran Mazumdar-Shaw to retire from Infosys board

ANI

Biocon Q1FY23 revenue up 23% at Rs 2,217 cr

IANS

Nykaa’s Falguni Nayar overtakes Kiran Mazumdar Shaw as the richest self-made Indian woman

Vaamanaa Sethi

Anil Ambani, Sachin Tendulkar, Kiran Shaw and other Indians named in the Pandora Papers leak

Rounak Jain

Catch Kiran Mazumdar Shaw at the Global Trends Festival 2020, speak about unlocking India's suppressed potential

BI India Bureau

India’s second richest woman nearly doubles her wealth to $4.6 billion during the COVID-19 pandemic

Preeti Soni

Actor Kiran Kumar tests positive for COVID-19

PTI

₹10,000 invested in Biocon just before lockdown is now worth over ₹16,500⁠— here’s why

BI India Bureau

India’s richest women as per Hurun list: Kiran Mazumdar Shaw and Smita Crishna on top

Rounak Jain

Puducherry Chief Minister V Narayanasamy resigns after Congress-led govt loses majority

Prabhjote Gill

Biocon’s Kiran Mazumdar Shaw, who debuted in the pharma industry with two employees and $500 becomes EY World Entrepreneur of the Year 2020

Prerna Sindwani

Popular Keywords

Buying Guides